Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_______________________________
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): June 30, 2010
 
Immunomedics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
 
Delaware 000-12104 61-1009366
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
 
 
300 American Road, Morris Plains, New Jersey 07950
(Address of Principal Executive Offices)
(Zip Code)
 
(973) 605-8200
(Registrant's telephone number,
including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[ ]    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
[ ]    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
[ ]    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
[ ]    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 
 
 
Item 8.01                      Other Events.
 
Effective June 30, 2010, Immunomedics, Inc. (the “Company”) terminated the services of American Stock Transfer and Trust Company as the Company’s transfer agent and registrar for shares of the Company’s common stock $0.01 par value per share (the “Common Stock”), and appointed StockTrans, Inc. to serve as the Company’s transfer agent and registrar for shares of the Company’s Common Stock.  Contact information for the Company’s transfer agent is as follows:
 
StockTrans, Inc.
44 West Lancaster Avenue
Ardmore, PA 19003
800-733-1121
 

 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
IMMUNOMEDICS, INC.
 
 
   By:   /s/ Cynthia L. Sullivan
     Name:  Cynthia L. Sullivan
     Title:  President and Chief Executive Officer
 
Dated:           June 30, 2010